1. Harmine targets inhibitor of DNA binding‐2 and activator protein‐1 to promote preosteoclast PDGF‐BB production
- Author
-
Yong Zhou, You-You Li, Hui Xie, Hao Yin, Zheng-Zhao Liu, Jie Huang, Yi-Yi Wang, Chun-Yuan Chen, Xiong-Ke Hu, Meng-Lu Chen, Kun Xia, Zhen-Xing Wang, Zheng-Guang Wang, and Jia Cao
- Subjects
0301 basic medicine ,Becaplermin ,Osteoclasts ,Id2 ,Pharmacology ,Mice ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Harmine ,preosteoclast ,Bone Marrow ,Animals ,Secretion ,Cells, Cultured ,Inhibitor of Differentiation Protein 2 ,Reporter gene ,Gene knockdown ,biology ,Activator (genetics) ,Chemistry ,Macrophages ,Original Articles ,Cell Biology ,AP‐1 ,Transcription Factor AP-1 ,030104 developmental biology ,Primary bone ,030220 oncology & carcinogenesis ,Hallucinogens ,Ovariectomized rat ,biology.protein ,Molecular Medicine ,Original Article ,PDGF‐BB ,Platelet-derived growth factor receptor - Abstract
Osteoporosis is one of the most common metabolic bone diseases affecting millions of people. We previously found that harmine prevents bone loss in ovariectomized mice via increasing preosteoclast platelet‐derived growth factor‐BB (PDGF‐BB) production and type H vessel formation. However, the molecular mechanisms by which harmine promotes preosteoclast PDGF‐BB generation are still unclear. In this study, we revealed that inhibitor of DNA binding‐2 (Id2) and activator protein‐1 (AP‐1) were important factors implicated in harmine‐enhanced preosteoclast PDGF‐BB production. Exposure of RANKL‐induced Primary bone marrow macrophages (BMMs), isolated from tibiae and femora of mice, to harmine increased the protein levels of Id2 and AP‐1. Knockdown of Id2 by Id2‐siRNA reduced the number of preosteoclasts as well as secretion of PDGF‐BB in RANKL‐stimulated BMMs administrated with harmine. Inhibition of c‐Fos or c‐Jun (components of AP‐1) both reversed the stimulatory effect of harmine on preosteoclast PDGF‐BB production. Dual‐luciferase reporter assay analyses determined that PDGF‐BB was the direct target of AP‐1 which was up‐regulated by harmine treatment. In conclusion, our data demonstrated a novel mechanism involving in the production of PDGF‐BB increased by harmine, which may provide potential therapeutic targets for bone loss diseases.
- Published
- 2021
- Full Text
- View/download PDF